Sunshine Biopharma, Inc. (SBFM) is a leader in the development and marketing of cancer drugs along with antiviral therapeutics. Its shares price rocketed higher by 53.4% to remain at $9.65 at the closing of Thursday’s regular trading. The price further leaped in today’s premarket session by 22.2%. The current stock price as of the writing stands at $11.9.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
SBFM: Recent Developments
SBFM updated on the effectivity of its newly developed mRNA molecule on April 05, as it is proven effective against culture-grown cancer cells. The cytotoxicity examination of the cells associated with breast, ovarian and pancreatic cancer reported little or no cytotoxic effect. The adaptability of the mRNA molecules is good in patients and the company will file a patent application with the outcomes soon.
SBFM: Industry Outlook
The financial experts consider that biotech stocks are experiencing a bumpy ride over the past year. Most biotech stocks are presumed to be volatile which makes the investors watchful. Some companies from this sector do have the ability to post huge gains. So, the analysts categorize biotech stocks as high-risk stocks.
SBFM: Company Outlook
SBFM is a nano-cap company also working on the development of COVID-19 treatment along with the cancer pipeline. Its collaboration with the University of Arizona was the result of the expansion of its COVID-19 drug development program. The financial highlights of the company include its revenue for the fiscal year 2021, which was $0.22 million along with a net loss of $12.4 million. The company’s stock is generally volatile with quick gains and quick losses seen instantly.
SBFM shares continue to rally and are making an impact in the industry as it is 534% up the last month. The reason behind the fabulous price gain is the volatility associated with penny stocks. The company updated on the effectiveness of its anti-cancer mRNA molecule, so the shares rose phenomenally.